abrdn plc Purchases 209,691 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

abrdn plc grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 910.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 232,716 shares of the biopharmaceutical company’s stock after acquiring an additional 209,691 shares during the quarter. abrdn plc owned 0.19% of Alnylam Pharmaceuticals worth $44,544,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the company. Harbor Capital Advisors Inc. lifted its position in shares of Alnylam Pharmaceuticals by 1.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after acquiring an additional 51 shares during the period. Captrust Financial Advisors lifted its position in shares of Alnylam Pharmaceuticals by 4.3% in the 2nd quarter. Captrust Financial Advisors now owns 1,285 shares of the biopharmaceutical company’s stock worth $187,000 after acquiring an additional 53 shares during the period. EP Wealth Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 6.4% in the 3rd quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 71 shares during the period. CIBC Asset Management Inc lifted its position in shares of Alnylam Pharmaceuticals by 2.0% in the 1st quarter. CIBC Asset Management Inc now owns 4,191 shares of the biopharmaceutical company’s stock worth $840,000 after acquiring an additional 84 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its position in shares of Alnylam Pharmaceuticals by 2.1% in the 3rd quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company’s stock worth $800,000 after acquiring an additional 93 shares during the period. Institutional investors own 92.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ALNY. Cantor Fitzgerald restated a “neutral” rating and set a $165.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, February 20th. Chardan Capital cut their target price on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating for the company in a research report on Friday, February 16th. Citigroup cut their target price on Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating for the company in a research report on Friday, February 16th. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday. Finally, Morgan Stanley cut their target price on Alnylam Pharmaceuticals from $184.00 to $176.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 13th. Nine equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $216.12.

Alnylam Pharmaceuticals Stock Performance

NASDAQ ALNY opened at $144.41 on Monday. The stock has a fifty day moving average of $151.56 and a 200-day moving average of $166.73. The stock has a market capitalization of $18.19 billion, a P/E ratio of -40.56 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52 week low of $143.50 and a 52 week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.10. The firm had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. During the same period last year, the business posted ($1.68) earnings per share. Equities research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.54 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.